Skip to main content
SpringerLink
Log in

Cariprazine in the Treatment of Psychosis

  • Reference work entry
  • First Online:
NeuroPsychopharmacotherapy

  • 74 Accesses

Abstract

Cariprazine is a dopamine D3 preferring D3/D2 receptor partial agonist antipsychotic indicated for the treatment of schizophrenia and bipolar disorders. Efficacy has been proven in randomized controlled studies, and the main indications are predominant negative symptoms in schizophrenia associated with the D3-receptor binding. Main side effects are akathisia, insomnia, and constipation. Compared with other antipsychotics, little effects on metabolic and cardiovascular parameters have been reported.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 949.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 1,399.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  • Ágai-Csongor É, Domány G, Nógrádi K, et al. Discovery of cariprazine (RGH-188): a novel antipsychotic acting on dopamine D3/D2 receptors. Bioorg Med Chem Lett. 2012;22:3437–40.

    Article  PubMed  Google Scholar 

  • Barabássy A, Sebe B, Acsai K, et al. Safety and tolerability of cariprazine in patients with schizophrenia: a pooled analysis of eight phase II/III studies. Neuropsychiatr Dis Treat. 2021;17:957–70.

    Article  PubMed  PubMed Central  Google Scholar 

  • Barth V, Need AB, Tzavara ET, et al. In vivo occupancy of dopamine D3 receptors by antagonists produces neurochemical and behavioral effects of potential relevance to attention-deficit-hyperactivity disorder. J Pharmacol Exp Ther. 2013;344:501–10.

    Article  CAS  PubMed  Google Scholar 

  • Bouthenet ML, Souil E, Martres MP, et al. Localization of dopamine D3 receptor mRNA in the rat brain using in situ hybridization histochemistry: comparison with dopamine D2 receptor mRNA. Brain Res. 1991;564:203–21.

    Article  CAS  PubMed  Google Scholar 

  • Calabrese JR, Keck PE Jr, Starace A, et al. Efficacy and safety of low-and high-dose cariprazine in acute and mixed mania associated with bipolar I disorder: a double-blind, placebo-controlled study. J Clin Psychiatry. 2015;76:284–92.

    Article  PubMed  Google Scholar 

  • Citrome L. Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability. Expert Opin Drug Metab Toxicol. 2013a;9:193–206.

    Article  CAS  PubMed  Google Scholar 

  • Citrome L. Cariprazine in schizophrenia: clinical efficacy, tolerability, and place in therapy. Adv Therap. 2013b;30:114–26.

    Article  CAS  Google Scholar 

  • Cutler AJ, Durgam S, Wang Y, et al. Evaluation of the long-term safety and tolerability of cariprazine in patients with schizophrenia: results from a 1-year open-label study. CNS Spectr. 2018;23:39–50.

    Article  PubMed  Google Scholar 

  • Durgam S, Starace A, Li D, et al. An evaluation of the safety and efficacy of cariprazine in patients with acute exacerbation of schizophrenia: a phase II, randomized clinical trial. Schizophr Res. 2014;152:450–7.

    Article  PubMed  Google Scholar 

  • Durgam S, Starace A, Li D, et al. The efficacy and tolerability of cariprazine in acute mania associated with bipolar I disorder: a phase II trial. Bipolar Disord. 2015a;17:63–75.

    Article  CAS  PubMed  Google Scholar 

  • Durgam S, Cutler AJ, Lu K, et al. Cariprazine in acute exacerbation of schizophrenia: a fixed-dose, phase 3, randomized, double-blind, placebo- and active-controlled trial. J Clin Psychiatry. 2015b;76:e1574–82.

    Article  PubMed  Google Scholar 

  • Durgam S, Earley W, Li R, et al. Long-term cariprazine treatment for the prevention of relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled trial. Schizophr Res. 2016a;176:264–71.

    Article  PubMed  Google Scholar 

  • Durgam S, Earley W, Lipschitz A, et al. An 8-week randomized, double-blind, placebo-controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. Am J Psychiatry. 2016b;173:271–81.

    Article  PubMed  Google Scholar 

  • Durgam S, Earley W, Lu K, Németh G, Laszlovszky I, Volk S, Litman RE. Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: a pooled post hoc analysis. Int J Clin Pract. 2017;71:e13037. https://doi.org/10.1111/ijcp.13037.

    Article  CAS  PubMed  Google Scholar 

  • Edinoff A, Ruoff M, Ghaffar Y, et al. Cariprazine to treat schizophrenia and bipolar disorder in adults. Psychopharmacol Bull. 2020;50:83–117.

    PubMed  PubMed Central  Google Scholar 

  • El-Mallakh RS, Elmaadawi AZ, Gao Y, Lohano K, Roberts RJ. Current and emerging therapies for the management of bipolar disorders. J Cent Nerv System Disord. 2011;3:189–97.

    CAS  Google Scholar 

  • Fagiolini A, Alcalá JÁ, Aubel T, et al. Treating schizophrenia with cariprazine: from clinical research to clinical practice. Real world experiences and recommendations from an international panel. Ann General Psychiatry. 2020;19:55. https://doi.org/10.1186/s12991-020-00305-3.

    Article  Google Scholar 

  • Fleischhacker W, Galderisi S, Laszlovszky I, et al. The efficacy of cariprazine in negative symptoms of schizophrenia: post hoc analyses of PANSS individual items and PANSS-derived factors. Eur Psychiatry. 2019;58:1–9.

    Article  PubMed  Google Scholar 

  • Garnock-Jones KP. Cariprazine: a review in schizophrenia. CNS Drugs. 2017;31:513–25.

    Article  CAS  PubMed  Google Scholar 

  • Horacek J, Bubenikova-Valesova V, Kopecek M, et al. Mechanism of action of atypical antipsychotic drugs and the neurobiology of schizophrenia. CNS Drugs. 2006;20:389–409.

    Article  CAS  PubMed  Google Scholar 

  • Kane JM, Zukin S, Wang Y, et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. J Clin Psychopharmacol. 2015;35:367–73.

    Article  CAS  PubMed  Google Scholar 

  • Kapur S, Remington G, Jones C, et al. High levels of dopamine D-2 receptor occupancy with low-dose haloperidol treatment: a PET study. Am J Psychiatry. 1996;153:948–50.

    Article  CAS  PubMed  Google Scholar 

  • Kapur S, Zipursky R, Roy P, et al. The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacology. 1997;131:148–52.

    Article  CAS  PubMed  Google Scholar 

  • Kirschner N, Gémesi LI, Vastag M, et al. In vitro metabolism of RGH-188. Presented at the 10th European International Society of the Study of Xenobiotics (ISSX), Meeting; May 18–21, 2008. Available from: https://issx.confex.com/issx/10euro/webprogram/Paper8686.html. Accessed 30 Sept 2015.

  • Kiss B, Horváth A, Némethy Z, et al. Cariprazine (RGH-188), a dopamine D3 receptor-preferring, D3/D2 dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Therap. 2010;333:328–40.

    Article  CAS  Google Scholar 

  • Lao K, He Y, Wong I, Besag F, Chan E. Tolerability and safety profile of cariprazine in treating psychotic disorders, bipolar disorder and major depressive disorder: a systematic review with meta-analysis of randomized controlled trials. CNS Drugs. 2016;30:1043–54. https://doi.org/10.1007/s40263-016-0382-z.

    Article  CAS  PubMed  Google Scholar 

  • Laszlovszky I, Barabassy A, Nemeth G. Cariprazine, a broad-spectrum antipsychotic for the treatment of schizophrenia: pharmacology, efficacy, and safety. Adv Ther. 2021;38:3652–73.

    Article  PubMed  PubMed Central  Google Scholar 

  • Madras BK. History of the discovery of the antipsychotic dopamine D2 receptor: a basis for the dopamine hypothesis of schizophrenia. J Hist Neurosci. 2013;22:62–78.

    Article  PubMed  Google Scholar 

  • Mészáros GP, Kapás M, Borsos M, et al. (P.3.c.047) Pharmacokinetics of RGH-188, a new dopamine D3/D2 antagonist/partial agonist atypical antipsychotic, in healthy subjects. Eur Neuropsychopharmacol. 2007;17(Suppl 4):S451–2.

    Article  Google Scholar 

  • Nasrallah H, Earley W, Cutler A, Wang Y, Lu K, Laszlovszky I, Németh G, Durgam S. The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis. BMC Psychiatry. 2017;24(17):305. https://doi.org/10.1186/s12888-017-1459-z.

    Article  CAS  Google Scholar 

  • Németh G, István Laszlovszky I, Pál Czobor P, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double-blind, controlled trial. Lancet. 2017;389:1103–13.

    Article  PubMed  Google Scholar 

  • Newman-Tacredi A. The importance of 5HT1A receptor agonism in antipsychotic drug action: rationale and perspectives. Curr Opin Investig Drugs. 2010;11:802–12.

    Google Scholar 

  • Nordström AL, Farde L, Wiesel FA, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects – a double-blind PET study of schizophrenic-patients. Biol Psychiatry. 1993;33:227–35.

    Article  PubMed  Google Scholar 

  • Papp M, Gruca P, Lasoń-Tyburkiewicz M, Adham N, Kiss B, Gyertyán I. Attenuation of anhedonia by cariprazine in the chronic mild stress model of depression. Behav Pharmacol. 2014;25:567–74.

    Article  CAS  PubMed  Google Scholar 

  • Pásztor Mészáros G, Agai-Csongor E, Kapaś M. Sensitive LC-MS/MS methods for the quantification of RGH-188 and its active metabolites, desmethyl- and didesmethyl-cariprazine in human plasma and urine. J Pharm Biomed Anal. 2008;48:388–97.

    Article  PubMed  Google Scholar 

  • Patel M, Jain R, Tohen M, et al. Efficacy of cariprazine in bipolar I depression across patient characteristics: a post hoc analysis of pooled randomized, placebo-controlled studies. Int Clin Psychopharmacol. 2021;36:76–83.

    Article  PubMed  Google Scholar 

  • Potkin S, Keator D, Mukherjee J, et al. (P.1.e.028) Dopamine D3 and D2 receptor occupancy of cariprazine in schizophrenic patients. Eur Neuropsychopharmacol. 2009;19(Suppl 3):S316.

    Article  Google Scholar 

  • Roberts RJ, Findlay LJ, El-Mallakh PL, El-Mallakh RS. Update on schizophrenia and bipolar disorder: focus on cariprazine. Neuropsychiatr Dis Treatt. 2016;12:1837–42.

    Article  CAS  Google Scholar 

  • Sachs GS, Greenberg WM, Starace A, et al. Cariprazine in the treatment of acute mania in bipolar I disorder: a double-blind, placebo-controlled, Phase III trial. J Affect Disord. 2015;174:296–302.

    Article  CAS  PubMed  Google Scholar 

  • Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatr. 2002;47:27–38.

    Article  Google Scholar 

  • Seneca N, Finnema SJ, Laszlovszky I, et al. Occupancy of dopamine D2 and D3 and serotonin 5-HT1A receptors by the novel antipsychotic drug candidate, cariprazine (RGH-188), in monkey brain measured using positron emission tomography. Psychopharmacology. 2011;218:579–87.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sheynikhovich D, Otani S, Arleo A. The role of tonic and phasic dopamine for long-term synaptic plasticity in the prefrontal cortex: a computational model. J Physiol Paris. 2011;105(1–3):45–52.

    PubMed  Google Scholar 

  • Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz J. Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature. 1990;347:146–51.

    Article  CAS  PubMed  Google Scholar 

  • Sokoloff P, Diaz J, Levesque D, et al. Novel dopamine receptor subtypes as targets for antipsychotic drugs. Ann N Y Acad Sci. 1995;757:278–92.

    Article  CAS  PubMed  Google Scholar 

  • Tohen M. Cariprazine as a treatment option for depressive episodes associated with bipolar 1 disorder in adults: an evidence-based review of recent data. Drug Des Devel Ther. 2021;15:2005–12.

    Article  PubMed  PubMed Central  Google Scholar 

  • Zhao M, Qin B, Wang J, Zhang Y, Zhao J, Mao Y, Zhang X, Zhang R. Efficacy and acceptability of cariprazine in acute exacerbation of schizophrenia: meta-analysis of randomized placebo-controlled trials. J Clin Psychopharmacol. 2018;38:55–9. https://doi.org/10.1097/JCP.0000000000000834.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. University Hospital Leipzig and Academic Hospital Arnsdorf, Leipzig/Arnsdorf, Germany

    Peter Schönknecht

Authors
  1. Peter Schönknecht
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Peter Schönknecht .

Editor information

Editors and Affiliations

  1. Clinic and Policlinic for Psychiatry, Psychosomatics and Psychotherapy, University Hospital Wuerzburg, Wuerzburg, Germany

    Peter Riederer

  2. Institute of Psychological Medicine (IPM), Soyen, Germany

    Gerd Laux

  3. Centre for Research Promotion and Support, Fujita Health University, Toyoake, Aichi, Japan

    Toshiharu Nagatsu

  4. Center Translational Res Neurol Diseases, Dalian Med Uni Shanghai Inst Health Sc Center Translational Res Neurol Diseases, Dalian, China

    Weidong Le

  5. Würzburg, Germany

    Christian Riederer

Section Editor information

  1. Department of Psychiatry, University Hospital Leipzig, Leipzig, Germany

    Frank Schmidt

Rights and permissions

Reprints and permissions

Copyright information

© 2022 Springer Nature Switzerland AG

About this entry

Check for updates. Verify currency and authenticity via CrossMark

Cite this entry

Schönknecht, P. (2022). Cariprazine in the Treatment of Psychosis. In: Riederer, P., Laux, G., Nagatsu, T., Le, W., Riederer, C. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-030-62059-2_118

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-62059-2_118

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-62058-5

  • Online ISBN: 978-3-030-62059-2

  • eBook Packages: MedicineReference Module Medicine

Publish with us

Policies and ethics

Search

Navigation